Member of the Association of American Physicians
Michael S. Saag mainly investigates Immunology, Acquired immunodeficiency syndrome, Internal medicine, Viral load and Virology. Michael S. Saag works mostly in the field of Immunology, limiting it down to topics relating to Protease inhibitor and, in certain cases, Ritonavir. His research integrates issues of Clinical research, Cohort study, Family medicine, Intensive care medicine and Cohort in his study of Acquired immunodeficiency syndrome.
His Internal medicine research is multidisciplinary, incorporating perspectives in Meningitis, Surgery, Mycosis, Flucytosine and Cryptococcosis. His work investigates the relationship between Viral load and topics such as Maraviroc that intersect with problems in CCR5 receptor antagonist and Vicriviroc. The concepts of his Virology study are interwoven with issues in Antibody and Gp41.
Michael S. Saag spends much of his time researching Internal medicine, Acquired immunodeficiency syndrome, Immunology, Viral load and Virology. His biological study spans a wide range of topics, including Gastroenterology and Surgery. Michael S. Saag has included themes like Mortality rate, Pediatrics, Cohort study and Intensive care medicine in his Acquired immunodeficiency syndrome study.
His studies in Immunology integrate themes in fields like Disease and Antiretroviral therapy. His work in Viral load addresses issues such as Efavirenz, which are connected to fields such as Pharmacology. His study in Virus, Zidovudine and Viral replication are all subfields of Virology.
The scientist’s investigation covers issues in Internal medicine, Acquired immunodeficiency syndrome, Cohort, Viral load and Hazard ratio. His Internal medicine study frequently links to other fields, such as Hepatitis C virus. His Acquired immunodeficiency syndrome study incorporates themes from Marginal structural model, Regimen, Pharmacotherapy and Clinical trial.
His work carried out in the field of Regimen brings together such families of science as Intensive care medicine, Pre-exposure prophylaxis, Reverse-transcriptase inhibitor and Emtricitabine. His Viral load study combines topics from a wide range of disciplines, such as Odds ratio, Viral suppression, Interquartile range, Epidemiology and Cohort study. Michael S. Saag interconnects Proportional hazards model and Confounding in the investigation of issues within Hazard ratio.
Michael S. Saag focuses on Internal medicine, Acquired immunodeficiency syndrome, Cohort, Viral load and Cohort study. His study on Internal medicine is mostly dedicated to connecting different topics, such as Antiretroviral therapy. The concepts of his Acquired immunodeficiency syndrome study are interwoven with issues in Coinfection and Regimen.
His Coinfection study deals with Abacavir intersecting with Intensive care medicine. His research integrates issues of Public health and Anxiety in his study of Cohort. His work deals with themes such as Odds ratio, Epidemiology and Myocardial infarction, which intersect with Viral load.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Viral dynamics in human immunodeficiency virus type 1 infection
Xiping Wei;Sajal K. Ghosh;Maria E. Taylor;Victoria A. Johnson.
Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study
Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka.
PLOS ONE (2015)
Antibody neutralization and escape by HIV-1
Xiping Wei;Julie M. Decker;Shuyi Wang;Huxiong Hui.
Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel
Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy.
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
Brandon F. Keele;Elena E. Giorgi;Elena E. Giorgi;Jesus F. Salazar-Gonzalez;Julie M. Decker.
Proceedings of the National Academy of Sciences of the United States of America (2008)
Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy
Xiping Wei;Julie M. Decker;Hongmei Liu;Zee Zhang.
Antimicrobial Agents and Chemotherapy (2002)
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
Piatak M;Saag Ms;Yang Lc;Clark Sj.
Effect of early versus deferred antiretroviral therapy for HIV on survival.
Mari M. Kitahata;Stephen J. Gange;Alison G. Abraham;Barry Merriman.
The New England Journal of Medicine (2009)
POTENT SUPPRESSION OF HIV-1 REPLICATION IN HUMANS BY T-20, A PEPTIDE INHIBITOR OF GP41-MEDIATED VIRUS ENTRY
J M Kilby;S Hopkins;T M Venetta;B DiMassimo.
Nature Medicine (1998)
Practice Guidelines for the Management of Cryptococcal Disease
Michael S. Saag;Richard J. Graybill;Robert A. Larsen;Peter G. Pappas.
Clinical Infectious Diseases (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: